OA11669A - 5HT1 receptor agonists and metoclopramide for the treatment of migraine. - Google Patents

5HT1 receptor agonists and metoclopramide for the treatment of migraine. Download PDF

Info

Publication number: OA11669A
Authority: OA; OAPI
Prior art keywords: metoclopramide; migraine; treatment; receptor agonist; eletriptan
Prior art date: 1998-10-30

Application number

OA1200100100A

Other languages

English (en)

Inventor

George Harry Sands

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-30

Filing date

1999-10-18

Publication date

2005-01-05

1999-10-18 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-01-05 Publication of OA11669A publication Critical patent/OA11669A/en

Links

208000019695 Migraine disease Diseases 0.000 title claims abstract description 26
206010027599 migraine Diseases 0.000 title claims abstract description 26
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 title claims abstract description 19
229960004503 metoclopramide Drugs 0.000 title claims abstract description 19
239000000018 receptor agonist Substances 0.000 title claims abstract description 19
229940044601 receptor agonist Drugs 0.000 title claims abstract description 19
108091005478 5-HT1 receptors Proteins 0.000 title abstract description 4
102000035038 5-HT1 receptors Human genes 0.000 title abstract description 4
241000124008 Mammalia Species 0.000 claims abstract description 12
229960002472 eletriptan Drugs 0.000 claims abstract description 10
OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 claims abstract description 10
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
239000003937 drug carrier Substances 0.000 claims abstract description 5
239000000203 mixture Substances 0.000 claims description 10
229960001360 zolmitriptan Drugs 0.000 claims description 7
UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims 3
238000001990 intravenous administration Methods 0.000 claims 2
238000000034 method Methods 0.000 abstract description 19
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 24
239000000556 agonist Substances 0.000 description 20
150000001875 compounds Chemical class 0.000 description 20
102000005962 receptors Human genes 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
239000000725 suspension Substances 0.000 description 13
239000000243 solution Substances 0.000 description 10
239000000872 buffer Substances 0.000 description 9
230000000694 effects Effects 0.000 description 9
-1 LY 306258 Chemical compound 0.000 description 8
125000000217 alkyl group Chemical group 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 7
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
238000012360 testing method Methods 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
229960003708 sumatriptan Drugs 0.000 description 5
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
239000001110 calcium chloride Substances 0.000 description 4
229910001628 calcium chloride Inorganic materials 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
125000001153 fluoro group Chemical group F* 0.000 description 4
239000008188 pellet Substances 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
235000010323 ascorbic acid Nutrition 0.000 description 3
229960005070 ascorbic acid Drugs 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
229960005254 naratriptan Drugs 0.000 description 3
UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 3
229960001779 pargyline Drugs 0.000 description 3
239000002287 radioligand Substances 0.000 description 3
229960000425 rizatriptan Drugs 0.000 description 3
TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
ASXGJMSKWNBENU-CQSZACIVSA-N (7R)-7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1=CC(O)=C2C[C@H](N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-CQSZACIVSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
241000700198 Cavia Species 0.000 description 2
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
101150015707 HTR1A gene Proteins 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
101100321769 Takifugu rubripes htr1d gene Proteins 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
239000003420 antiserotonin agent Substances 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
238000011597 hartley guinea pig Methods 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
125000002950 monocyclic group Chemical group 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
239000000843 powder Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000012216 screening Methods 0.000 description 2
210000003523 substantia nigra Anatomy 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
FMXXORRZIQGUIN-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-[3-[3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1h-indol-5-yl]-n-methylmethanesulfonamide Chemical compound OC(=O)\C=C\C(O)=O.C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1CCCN(CC1)CCN1C1=NC=NC=C1OC FMXXORRZIQGUIN-WLHGVMLRSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
QZAYGJVTTNCVMB-PZFLKRBQSA-N 3-(2-amino-1,2-ditritioethyl)-1h-indol-5-ol Chemical compound C1=C(O)C=C2C(C([3H])C(N)[3H])=CNC2=C1 QZAYGJVTTNCVMB-PZFLKRBQSA-N 0.000 description 1
OFCNTYBPPAQCRE-UHFFFAOYSA-N 3-(2-aminoethyl)-3h-indol-5-ol Chemical compound C1=C(O)C=C2C(CCN)C=NC2=C1 OFCNTYBPPAQCRE-UHFFFAOYSA-N 0.000 description 1
FFDNNYPJMOZSMU-UHFFFAOYSA-N 3-[(1-methylpyrrolidin-2-yl)methyl]-n-(3-nitro-2h-pyridin-3-yl)-1h-indol-5-amine Chemical compound CN1CCCC1CC(C1=C2)=CNC1=CC=C2NC1([N+]([O-])=O)C=CC=NC1 FFDNNYPJMOZSMU-UHFFFAOYSA-N 0.000 description 1
HCXROGVQIBVJTA-UHFFFAOYSA-N 3-[[3-[3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1h-indol-5-yl]amino]-4-methylcyclobut-3-ene-1,2-dione Chemical compound COC1=CN=CN=C1N1CCN(CCCC=2C3=CC(NC=4C(C(=O)C=4C)=O)=CC=C3NC=2)CC1 HCXROGVQIBVJTA-UHFFFAOYSA-N 0.000 description 1
MDMJLMDBRQXOOI-UHFFFAOYSA-N 4-fluoro-n-[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2NC(=O)C1=CC=C(F)C=C1 MDMJLMDBRQXOOI-UHFFFAOYSA-N 0.000 description 1
229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 description 1
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 description 1
102100027493 5-hydroxytryptamine receptor 1D Human genes 0.000 description 1
WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000017911 HTR1A Human genes 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
JLVHTNZNKOSCNB-YSVLISHTSA-N Mesulergine Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CN(C)C3=C1 JLVHTNZNKOSCNB-YSVLISHTSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
229960002133 almotriptan Drugs 0.000 description 1
229950001123 alniditan Drugs 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000002460 anti-migrenic effect Effects 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940125684 antimigraine agent Drugs 0.000 description 1
239000002282 antimigraine agent Substances 0.000 description 1
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
229960004046 apomorphine Drugs 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
229950002360 avitriptan Drugs 0.000 description 1
WRZVGHXUPBWIOO-UHFFFAOYSA-N avitriptan Chemical compound C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1CCCN(CC1)CCN1C1=NC=NC=C1OC WRZVGHXUPBWIOO-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000012636 effector Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
229960002284 frovatriptan Drugs 0.000 description 1
SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 1
239000007789 gas Substances 0.000 description 1
208000001288 gastroparesis Diseases 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
239000013029 homogenous suspension Substances 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229950008693 mesulergine Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
FUAXXSWWKCVWMD-UHFFFAOYSA-N n,n-dipropyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2C(N(CCC)CCC)CCCC2=C1 FUAXXSWWKCVWMD-UHFFFAOYSA-N 0.000 description 1
QVSXOXCYXPQXMF-OAHLLOKOSA-N n-[[(2r)-3,4-dihydro-2h-chromen-2-yl]methyl]-n'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine Chemical compound C([C@@H]1OC2=CC=CC=C2CC1)NCCCNC1=NCCCN1 QVSXOXCYXPQXMF-OAHLLOKOSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229950007002 phosphocreatine Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
238000013105 post hoc analysis Methods 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000047 product Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
229940100618 rectal suppository Drugs 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
210000003752 saphenous vein Anatomy 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000009738 saturating Methods 0.000 description 1
239000004003 serotonin 1D agonist Substances 0.000 description 1
239000000387 serotonin 5-HT4 receptor agonist Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
XREXPQGDOPQPAH-QKUPJAQQSA-K trisodium;[(z)-18-[1,3-bis[[(z)-12-sulfonatooxyoctadec-9-enoyl]oxy]propan-2-yloxy]-18-oxooctadec-9-en-7-yl] sulfate Chemical compound [Na+].[Na+].[Na+].CCCCCCC(OS([O-])(=O)=O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O)COC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O XREXPQGDOPQPAH-QKUPJAQQSA-K 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

OA1200100100A 1998-10-30 1999-10-18 5HT1 receptor agonists and metoclopramide for the treatment of migraine. OA11669A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10632898P	1998-10-30	1998-10-30

Publications (1)

Publication Number	Publication Date
OA11669A true OA11669A (en)	2005-01-05

Family

ID=22310818

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100100A OA11669A (en)	1998-10-30	1999-10-18	5HT1 receptor agonists and metoclopramide for the treatment of migraine.

Country Status (34)

Country	Link
US (2)	US6255334B1 (fr)
EP (1)	EP1126840A1 (fr)
JP (1)	JP2002528497A (fr)
KR (1)	KR20010089363A (fr)
CN (1)	CN1325304A (fr)
AP (1)	AP2001002129A0 (fr)
AR (1)	AR019246A1 (fr)
AU (1)	AU5994799A (fr)
BG (1)	BG105534A (fr)
BR (1)	BR9914901A (fr)
CA (1)	CA2348543A1 (fr)
CO (1)	CO4950530A1 (fr)
CZ (1)	CZ20011468A3 (fr)
EA (1)	EA200100284A1 (fr)
EE (1)	EE200100243A (fr)
GT (1)	GT199900189A (fr)
HK (1)	HK1040929A1 (fr)
HR (1)	HRP20010298A2 (fr)
HU (1)	HUP0104696A3 (fr)
ID (1)	ID28291A (fr)
IL (1)	IL141957A0 (fr)
IS (1)	IS5898A (fr)
MA (1)	MA26702A1 (fr)
NO (1)	NO20012013D0 (fr)
OA (1)	OA11669A (fr)
PA (1)	PA8484801A1 (fr)
PE (1)	PE20001284A1 (fr)
PL (1)	PL347541A1 (fr)
SK (1)	SK5522001A3 (fr)
TN (1)	TNSN99203A1 (fr)
TR (1)	TR200101174T2 (fr)
TW (1)	TW524692B (fr)
WO (1)	WO2000025778A1 (fr)
ZA (1)	ZA200103322B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0105131D0 (en) *	2001-03-01	2001-04-18	Pfizer Ltd	Compositions having improved bioavailability
US6579898B2 (en) *	2001-03-01	2003-06-17	Pfizer Inc.	Compositions having improved bioavailability
WO2002094242A1 (fr) *	2001-05-24	2002-11-28	Alexza Molecular Delivery Corporation	Administration de rizatriptan ou de zolmitriptan par voie d'inhalation
US7498019B2 (en)	2001-05-24	2009-03-03	Alexza Pharmaceuticals, Inc.	Delivery of compounds for the treatment of headache through an inhalation route
US20030051728A1 (en)	2001-06-05	2003-03-20	Lloyd Peter M.	Method and device for delivering a physiologically active compound
US7090830B2 (en)	2001-05-24	2006-08-15	Alexza Pharmaceuticals, Inc.	Drug condensation aerosols and kits
US7458374B2 (en)	2002-05-13	2008-12-02	Alexza Pharmaceuticals, Inc.	Method and apparatus for vaporizing a compound
US7078016B2 (en)	2001-11-21	2006-07-18	Alexza Pharmaceuticals, Inc.	Delivery of caffeine through an inhalation route
US7645442B2 (en)	2001-05-24	2010-01-12	Alexza Pharmaceuticals, Inc.	Rapid-heating drug delivery article and method of use
JP2005503425A (ja) *	2001-05-24	2005-02-03	アレックザモレキュラーデリヴァリーコーポレイション	所定の吸入ルートによる薬剤エステルの送出
US7585493B2 (en)	2001-05-24	2009-09-08	Alexza Pharmaceuticals, Inc.	Thin-film drug delivery article and method of use
US20070122353A1 (en)	2001-05-24	2007-05-31	Hale Ron L	Drug condensation aerosols and kits
ATE415155T1 (de) *	2001-05-24	2008-12-15	Alexza Pharmaceuticals Inc	Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation
WO2003041693A1 (fr) *	2001-11-09	2003-05-22	Alexza Molecular Delivery Corporation	Administration de diazepam a travers une voie pulmonaire
WO2003094900A1 (fr)	2002-05-13	2003-11-20	Alexza Molecular Delivery Corporation	Distribution de medicament a base d'amines par voie d'inhalation
US7550133B2 (en)	2002-11-26	2009-06-23	Alexza Pharmaceuticals, Inc.	Respiratory drug condensation aerosols and methods of making and using them
US20040105818A1 (en)	2002-11-26	2004-06-03	Alexza Molecular Delivery Corporation	Diuretic aerosols and methods of making and using them
JP2006514934A (ja)	2002-11-26	2006-05-18	アレックザファーマシューティカルズ，インコーポレイテッド	疼痛治療用薬剤製造のためのロキサピンまたはアモキサピンの使用
US7913688B2 (en)	2002-11-27	2011-03-29	Alexza Pharmaceuticals, Inc.	Inhalation device for producing a drug aerosol
US20040234916A1 (en)	2003-05-21	2004-11-25	Alexza Molecular Delivery Corporation	Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
US7540286B2 (en)	2004-06-03	2009-06-02	Alexza Pharmaceuticals, Inc.	Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20060002989A1 (en) *	2004-06-10	2006-01-05	Ahmed Salah U	Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US20050282879A1 (en) *	2004-06-17	2005-12-22	Foad Salehani	Methods and composition for treatment of migraine and symptoms thereof
EP1781360A1 (fr)	2004-08-12	2007-05-09	Alexza Pharmaceuticals, Inc.	Dispositif de distribution de drogue par aérosol intégrant des conditionnements thermiques actionnés par percussion
ZA200709038B (en) *	2005-04-13	2009-01-28	Neuraxon Inc	Substituted indole compounds having nos inhibitory activity
CN101466709B (zh) *	2006-04-13	2013-03-20	轴突公司	具有nos抑制活性的1,5和3,6-取代的吲哚化合物
US20080139510A1 (en) *	2006-12-07	2008-06-12	Abe Rose	Treatment of migraine headaches with sublingual amino acids
WO2008112661A2 (fr)	2007-03-09	2008-09-18	Alexza Pharmaceuticals, Inc.	Unité chauffante à utiliser dans un dispositif d'administration de médicament
EP2219449A4 (fr) *	2007-11-16	2010-10-27	Univ Arizona State	Procédés de traitement de la douleur viscérale
WO2009062318A1 (fr) *	2007-11-16	2009-05-22	Neuraxon, Inc.	Composés d'indole 3,5-substitués ayant une activité d'inhibition de la réabsorption de la nos et de la noradrénaline
EA201000808A1 (ru) *	2007-11-16	2011-04-29	Ньюраксон, Инк.	Индольные соединения и способы лечения висцеральной боли
AU2013202680C1 (en) *	2008-04-28	2016-06-23	Zogenix, Inc.	Novel formulations for treatment of migraine
US12214118B2 (en)	2018-02-02	2025-02-04	Alexza Pharmaceuticals, Inc.	Electrical condensation aerosol device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5698571A (en) *	1994-10-05	1997-12-16	Eli Lilly And Company	5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
WO1998002186A1 (fr) *	1996-07-11	1998-01-22	Farmarc Nederland B.V.	Compose d'inclusion contenant un agoniste selectif de la serotonine a structure indole
GB9709739D0 (en)	1997-05-14	1997-07-02	Merck Sharp & Dohme	Pharmaceutical formulation

1999
- 1999-09-01 US US09/387,990 patent/US6255334B1/en not_active Expired - Fee Related
- 1999-10-18 WO PCT/IB1999/001694 patent/WO2000025778A1/fr not_active Ceased
- 1999-10-18 EE EEP200100243A patent/EE200100243A/xx unknown
- 1999-10-18 BR BR9914901-0A patent/BR9914901A/pt not_active IP Right Cessation
- 1999-10-18 OA OA1200100100A patent/OA11669A/en unknown
- 1999-10-18 AP APAP/P/2001/002129A patent/AP2001002129A0/en unknown
- 1999-10-18 HK HK02102736.3A patent/HK1040929A1/zh unknown
- 1999-10-18 CZ CZ20011468A patent/CZ20011468A3/cs unknown
- 1999-10-18 CA CA002348543A patent/CA2348543A1/fr not_active Abandoned
- 1999-10-18 IL IL14195799A patent/IL141957A0/xx unknown
- 1999-10-18 HR HR20010298A patent/HRP20010298A2/hr not_active Application Discontinuation
- 1999-10-18 AU AU59947/99A patent/AU5994799A/en not_active Abandoned
- 1999-10-18 JP JP2000579219A patent/JP2002528497A/ja active Pending
- 1999-10-18 HU HU0104696A patent/HUP0104696A3/hu unknown
- 1999-10-18 EA EA200100284A patent/EA200100284A1/ru unknown
- 1999-10-18 ID IDW00200100930A patent/ID28291A/id unknown
- 1999-10-18 SK SK552-2001A patent/SK5522001A3/sk unknown
- 1999-10-18 KR KR1020017005271A patent/KR20010089363A/ko not_active Ceased
- 1999-10-18 TR TR2001/01174T patent/TR200101174T2/xx unknown
- 1999-10-18 CN CN99812756A patent/CN1325304A/zh active Pending
- 1999-10-18 EP EP99971318A patent/EP1126840A1/fr not_active Withdrawn
- 1999-10-18 PL PL99347541A patent/PL347541A1/xx not_active Application Discontinuation
- 1999-10-27 PA PA19998484801A patent/PA8484801A1/es unknown
- 1999-10-27 TN TNTNSN99203A patent/TNSN99203A1/fr unknown
- 1999-10-27 MA MA25827A patent/MA26702A1/fr unknown
- 1999-10-27 TW TW088118594A patent/TW524692B/zh active
- 1999-10-28 AR ARP990105447A patent/AR019246A1/es not_active Application Discontinuation
- 1999-10-29 PE PE1999001083A patent/PE20001284A1/es not_active Application Discontinuation
- 1999-10-29 CO CO99068659A patent/CO4950530A1/es unknown
- 1999-10-29 GT GT199900189A patent/GT199900189A/es unknown
2001
- 2001-03-16 IS IS5898A patent/IS5898A/is unknown
- 2001-04-19 US US09/838,440 patent/US20010020036A1/en not_active Abandoned
- 2001-04-24 ZA ZA200103322A patent/ZA200103322B/en unknown
- 2001-04-24 NO NO20012013A patent/NO20012013D0/no not_active Application Discontinuation
- 2001-05-22 BG BG105534A patent/BG105534A/xx unknown

Also Published As

Publication number	Publication date
WO2000025778A1 (fr)	2000-05-11
US6255334B1 (en)	2001-07-03
MA26702A1 (fr)	2004-12-20
JP2002528497A (ja)	2002-09-03
CO4950530A1 (es)	2000-09-01
HRP20010298A2 (en)	2002-06-30
AR019246A1 (es)	2001-12-26
IL141957A0 (en)	2002-03-10
CN1325304A (zh)	2001-12-05
TNSN99203A1 (fr)	2005-11-10
HUP0104696A2 (hu)	2002-05-29
KR20010089363A (ko)	2001-10-06
TR200101174T2 (tr)	2001-10-22
EA200100284A1 (ru)	2001-10-22
PL347541A1 (en)	2002-04-08
HK1040929A1 (zh)	2002-06-28
IS5898A (is)	2001-03-16
AU5994799A (en)	2000-05-22
BG105534A (en)	2001-12-29
EP1126840A1 (fr)	2001-08-29
NO20012013L (no)	2001-04-24
TW524692B (en)	2003-03-21
PA8484801A1 (es)	2000-09-29
HUP0104696A3 (en)	2003-05-28
NO20012013D0 (no)	2001-04-24
GT199900189A (es)	2001-04-21
EE200100243A (et)	2002-12-16
AP2001002129A0 (en)	2001-06-30
CA2348543A1 (fr)	2000-05-11
ID28291A (id)	2001-05-10
PE20001284A1 (es)	2000-11-22
CZ20011468A3 (cs)	2002-04-17
SK5522001A3 (en)	2002-05-09
ZA200103322B (en)	2002-06-10
US20010020036A1 (en)	2001-09-06
BR9914901A (pt)	2001-07-17

Publication	Publication Date	Title
OA11669A (en)	2005-01-05	5HT1 receptor agonists and metoclopramide for the treatment of migraine.
CN107921035B (zh)	2021-08-31	高苯丙氨酸血症及其治疗
AU3873401A (en)	2001-10-25	Compositions and methods for treating female sexual dysfunction
ES2204154T3 (es)	2004-04-16	Ligandos del receptor 5-ht-1 azabiciclicos.
IE912237A1 (en)	1992-01-01	Pharmaceutical preparations
AU3400900A (en)	2000-11-16	5HT1 receptor agonist and either a Cox-2 inhibitor or NSAID for the treatment of migraine
US20030216458A1 (en)	2003-11-20	Combination therapy for the treatment of migraine
EP0635269B1 (fr)	1999-11-03	Utilisation de N-(pyridinyl)-1H-indol-1-amines pour la fabrication de médicaments pour le traitement des maladies obséssives-compulsives
AU3253800A (en)	2000-11-16	Combination therapy for the treatment of migraine
AU4273000A (en)	2001-01-04	5HT1 receptor agonists, caffeine and either A COX-2 inhibitor or NSAID for the treatment of migraine
EP1115404B1 (fr)	2004-01-14	Utilisation d'antagonistes de prostanoides pour le traitement de cephalees primaires
MXPA01004297A (en)	2001-12-04	5ht1
NL8700191A (nl)	1987-08-17	Immunosuppressieve middelen, farmaceutische preparaten die ze bevatten en het toepassen van deze middelen.
ZA200109049B (en)	2003-02-03	New pharmaceutically active compounds.